Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Original Article
L.A. Castellucci, V.M. Chen, M.J. Kovacs, A. Lazo-Langner, P. Greenstreet, S. Kahn, B. Côté, S. Schulman, K.d. Wit, J. Douketis, D. Suryanarayan, T. Wan, E. Yeo, G.L. Templier, H.A. Tran, A. Willcox, H.J. Crowther, R. Prasad, S. Shivakumar, E. Umana, F.N. Ainle, T. Tritschler, S. Barco, J.-P. Galanaud, M. Blondon, L.B. Kreuziger, S. Solymoss, C. Kearon, E. Thomas, T. Ramsay, G.L. Gal, and M. Rodger
N Engl J Med 2026;394:1051-1060
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Please sign in or create an account to take the course.

Facebook
X
LinkedIn
Forward